Focused On-demand Library for RNA-splicing ligase RtcB homolog

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

3'-phosphate/5'-hydroxy nucleic acid ligase

Alternative UPACC:

Q9Y3I0; B2R6A8; Q6IAI0; Q9BWL4; Q9NTH1; Q9P037; Q9P0J3


RNA-splicing ligase RtcB homolog, also known as 3'-phosphate/5'-hydroxy nucleic acid ligase, plays a pivotal role in RNA processing. It acts as a catalytic subunit within the tRNA-splicing ligase complex, joining spliced tRNA halves into mature tRNAs. This process incorporates the precursor-derived splice junction phosphate into the mature tRNA, showcasing its essential function in RNA ligase activity with broad substrate specificity.

Therapeutic significance:

Understanding the role of RNA-splicing ligase RtcB homolog could open doors to potential therapeutic strategies. Its critical function in RNA processing highlights its potential as a target for interventions in diseases where RNA splicing and processing are compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.